Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

11.64 -1.27

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.59

Max

11.72

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+153.87% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-80M 1B
Ouverture précédente	12.91
Clôture précédente	11.64

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 sept. 2026, 23:31 UTC

S&P Global Manufacturing PMI for South Korea set to release on October 1, 2026, amid cautious market expectations influenced by rising energy prices and geopolitical tensions.

26 sept. 2026, 23:31 UTC

S&P/Case-Shiller Home Price Index Set for Release with Anticipated 2.2% Growth Amid Mixed Market Sentiment and Economic Pressures

26 sept. 2026, 23:31 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to show growth trends amid recent fluctuations.

26 sept. 2026, 23:22 UTC

U.S. Q2 GDP Growth Rate Forecasted at +1.6% Amid Economic Concerns and Market Volatility Ahead of September 30 Release

26 sept. 2026, 23:22 UTC

Upcoming PCE Price Index release on September 30 raises inflation concerns amid rising commodity prices and geopolitical tensions.

26 sept. 2026, 23:22 UTC

U.S. Personal Spending Expected to Rise 0.8% in August Amid Caution Over Inflation and Consumer Confidence Decline

26 sept. 2026, 23:22 UTC

Upcoming U.S. Retail Inventories Ex Autos Report on September 30 Expected to Reflect Consumer Demand Amid Mixed Economic Signals.

26 sept. 2026, 23:22 UTC

U.S. Goods Trade Balance Report Set for Release Amid Anticipated $108.5 Billion Deficit and Positive Tariff Negotiations with China

26 sept. 2026, 23:22 UTC

US Personal Income Expected to Rise 0.4% in August Amid Economic Recovery and Inflation Concerns

26 sept. 2026, 23:22 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% Amid Mixed Investor Sentiment and Inflation Concerns Ahead of September Release

26 sept. 2026, 23:22 UTC

U.S. GDP Price Index Expected to Rise 0.064% Amid Mixed Economic Sentiment and Inflation Concerns Ahead of September Release

26 sept. 2026, 23:22 UTC

Core PCE Price Index MoM for August 2026 set to release on September 30, with a forecasted increase of 0.3%, amid cautious investor sentiment and rising treasury yields impacting Fed policy outlook.

26 sept. 2026, 23:22 UTC

U.S. PCE Price Index Release on September 30 Expected to Show 0.4% Monthly Increase Amid Inflation Concerns and Market Volatility

26 sept. 2026, 23:11 UTC

Cautious Market Anticipates 70,000 Job Increase in Upcoming ADP Employment Report Amid Recent Underperformance

26 sept. 2026, 23:11 UTC

Mexican Business Confidence Remains Cautious Ahead of October EMOE Release Amid U.S. Economic Concerns

26 sept. 2026, 23:11 UTC

Correlated Moves

Avalanche is trading higher, continuing its upward trend since Friday, while Ethereum remains little changed amid broader market support from easing oil prices and Treasury yields.

26 sept. 2026, 23:01 UTC

Canada's Preliminary Monthly GDP Release on September 29 Expected to Show Stability Amid Economic Challenges and Trade Tensions.

26 sept. 2026, 23:01 UTC

South Korea's October 1 export report expected to show continued strong growth, following August's impressive 68.7% surge driven by memory chip demand.

26 sept. 2026, 22:51 UTC

Japan's unemployment rate forecasted to drop slightly to 2.4% in August, amid cautious market optimism and concerns over currency depreciation and rising interest rates ahead of the October release.

26 sept. 2026, 22:51 UTC

South Africa's Balance of Trade report on September 30, 2026, expected to show continued trade surplus amid cautious optimism in exports and declining imports.

26 sept. 2026, 22:51 UTC

Germany's Inflation Rate Release on September 30, 2026: Consumer Confidence Declines Amid Rising Energy Prices and Economic Uncertainty.

26 sept. 2026, 22:51 UTC

Japan's Tankan Index Set for Positive Release Amid Cautious Market Optimism and Global Economic Pressures

26 sept. 2026, 22:51 UTC

Germany's Inflation Rate Expected to Rise 0.5% Amid Declining Consumer Confidence Due to Soaring Energy Prices

26 sept. 2026, 22:51 UTC

Macro News

The Russell 2000 Index is trading lower in after-hours, reflecting a slight decline since Friday's close, amid rising delinquency rates in the commercial real estate sector.

26 sept. 2026, 22:51 UTC

Macro News

The Dow Jones Index is lower in after-market trading, amid trade tariff discussions and rising delinquency rates in commercial real estate.

26 sept. 2026, 22:51 UTC

Macro News

The FTSE 100 Index has advanced modestly in after-market hours, following a U.S.-China tariff agreement on $30 billion in goods.

26 sept. 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Hits 7.12%, Highest Since May, Amid Rising Treasury Yields and Inflation Concerns

26 sept. 2026, 22:40 UTC

Macro News

The DAX 30 Index is trading modestly lower in after-market hours, continuing its downward trend amid ongoing macroeconomic concerns and trade developments.

26 sept. 2026, 22:31 UTC

Japan's Industrial Production Expected to Rise 1.7% in August Amidst Cautious Optimism and Global Uncertainties

26 sept. 2026, 22:31 UTC

Japan's Retail Sales YoY data for August expected to rise 3.3% amid cautious optimism and inflation concerns, with market focus on currency valuation and global trends.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

153.87% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 153.87%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.